The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz
EndocrinologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- AIDS (London, England)
- Publicado em
- 15 dez 2021
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz
Sumbul Asif, Evangelia Baxevanidi, Andrew Hill, Willem Daniel Francois Venter, Lee Fairlie, Masebole Masenya, Celicia Serenata, Simiso Sokhela, Nomathemba Chandiwana
Descritores MeSH
- Pregnancy Outcome
- Anti-HIV Agents
- Obesity
- Alanine
- Alkynes
- Cyclopropanes
- Female
- Heterocyclic Compounds, 3-Ring
- Humans
- Oxazines
Veja também
Estudos relacionados
- Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV
- Hipertensão num Ensaio Aleatório de Mulheres Grávidas e Pós- Parto com HIV
- Bone Mineral Content, Growth, and Renal Health of Infants With Perinatal Exposure to Maternal Dolutegravir Versus Efavirenz and Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide: The Randomized IMPAACT 2010 (VESTED) Trial
- Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants